About the Study: Among patients undergoing urgent coronary intervention for acute myocardial infarction, starting evolocumab before or during the procedure produced faster and more sustained LDL cholesterol lowering than a conventional stepwise treatment approach. However, this strategy did not reduce death or unplanned cardiovascular hospitalization during the first year. The findings do not support the assumption that lowering LDL cholesterol as rapidly as possible with a PCSK9 inhibitor immediately after myocardial infarction necessarily improves short-term clinical outcomes.
Meeting Information: ESC 2026
This paper will be presented during European Society of Cardiology Congress in Munich, Germany.
Local Embargo Time: 8:30 A.M. CEST.
ESC Presentation: Gilles Montalescot will simultaneously present the findings during the Hot Line 2 session in the Main Auditorium.
Related Content: This paper has an accompanying editorial .
Corresponding Author: Gilles Montalescot, MD, PhD, ACTION Study Group, Hôpital Pitié-Salpêtrière (AP-HP), Bureau #1, 2ème étage, 47-83 bld de l’Hôpital, 75013 Paris, France ( gilles.montalescot@aphp.fr ).
10.1001/jama.2026.17302
To access the embargoed study: Visit our JAMA Network Media Center at this link https://media.jamanetwork.com/
Link to the article in your story
We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)
Editor's Note: Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
JAMA
LDL Cholesterol Lowering With Evolocumab Before Percutaneous Coronary Intervention for Acute Myocardial Infarction (AMUNDSEN)